US OptionsDetailed Quotes
SLRN240719C5000
- 1.50
- -0.65-30.23%
15min DelayClose Jul 19 16:00 ET
1.50High1.50Low
1.50Open2.15Pre Close1 Volume43 Open Interest5.00Strike Price150.00Turnover7048.51%IV-0.15%PremiumJul 19, 2024Expiry Date1.51Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.7663Delta0.0665Gamma2.66Leverage Ratio-19.6818Theta0.0000Rho2.04Eff Leverage0.0002Vega
Acelyrin Stock Discussion
Sign in to post a comment
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
$Acelyrin(SLRN.US$ insider buying?good news soon?
The company's CEO sees Tetrault's extensive experience, especially in global human capital strategy and business operations, as a valuable addition to support the evolution of the company.
Sequencing errors and subsequent audit could sway product development path and trigger a shift of ongoing studies to a new CRO, possibly impacting the company's financial health and milestones despite strong cash position.
Insiders remain bullish about the company, implied by the purchase made by the Independent Director even at prices higher than current rate. This suggests a reasonable alignment between the company leadership and shareholder interests.
CEO Dr. Lin expressed confidence in Patricia Turney's appointment, banking on her extensive expertise for ACELYRIN's growth phase. Turney is excited to contribute towards maintaining high-quality standards.
$Acelyrin(SLRN.US$ bottom rebound. looks like up to $19 from here (JP Morgan)
$Acelyrin(SLRN.US$
Lookimg for more dips 😝
Lookimg for more dips 😝
1
No comment yet
diamonds : Excuse me, can shares held still be valid after ENDPQ's restructuring?